#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14078	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2513	687.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1896	1896	T	885	T,C,G,A	877,3,3,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14078	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2513	687.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1630	1630	C	926	C,A	924,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24198	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4171	723.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1899	1899	A	1011	A	1011	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24198	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4171	723.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2533	2533	C	888	C,T,G	875,12,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24198	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4171	723.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2607	2607	A	833	A	833	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24198	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4171	723.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3159	3159	C	797	C	797	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	539	72866	blaTEM	861	861	99.88	blaTEM.l15.c17.ctg.1	2150	4229.2	0	.	p	.	0	M180T	NONSYN	538	540	ATG	1157	1159	ACG	6703;6723;6696	A,C,G,T;C,A,T,G;G,T,C,A	6693,6,3,1;6718,3,1,1;6685,4,4,3	.	Betalactam resistance
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2000	folP	855	855	100.0	folP.l15.c4.ctg.1	2031	122.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1292	1294	AGC	191;192;193	A;G,C;C	191;191,1;193	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5154	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3880	165.9	1	SNP	p	D95N	1	D95N	NONSYN	283	285	GAC	867	869	AAC	182;183;187	A;A,G;C	182;182,1;187	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5154	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3880	165.9	1	SNP	p	S91F	0	.	.	271	273	TCC	855	857	TCC	183;183;184	T;C;C	183;183;184	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	1918	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1967	121.8	1	SNP	p	G45D	1	.	.	133	135	GAC	830	832	GAC	203;203;203	G;A;C	203;203;203	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1048	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1548	84.4	0	.	n	.	0	A197.	DEL	197	197	A	903	903	A	215	A	215	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3601	156.4	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1924	1926	GCA	192;192;192	G;C;A	192;192;192	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3601	156.4	1	SNP	p	D86N	0	.	.	256	258	GAC	877	879	GAC	201;201;201	G,A;A,C;C,T	200,1;200,1;200,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3601	156.4	1	SNP	p	S87I	0	.	.	259	261	AGT	880	882	AGT	200;201;201	A;G;T	200;201;201	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3601	156.4	1	SNP	p	S87R	0	.	.	259	261	AGT	880	882	AGT	200;201;201	A;G;T	200;201;201	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3601	156.4	1	SNP	p	S87W	0	.	.	259	261	AGT	880	882	AGT	200;201;201	A;G;T	200;201;201	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4512	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3601	156.4	1	SNP	p	S88P	0	.	.	262	264	TCC	883	885	TCC	200;200;198	T;C;C	200;200;198	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3860	parE	1986	1986	99.9	parE.l15.c4.ctg.1	3263	147.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1889	1891	GGC	191;192;192	G;G;C,G	191;192;191,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	3998	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3002	166.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1537	1539	GCA	230;227;231	G,C,T;C;A	227,2,1;227;231	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3998	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3002	166.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1540	1542	ATC	231;232;232	A;T;C	231;232;232	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3998	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3002	166.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1552	1554	GTG	225;226;224	G;T;G	225;226;224	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3998	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3002	166.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1552	1554	GTG	225;226;224	G;T;G	225;226;224	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3998	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3002	166.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2056	2058	ACC	231;232;230	A;C,T;C	231;231,1;230	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3998	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3002	166.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2110	2112	GCG	222;222;221	G;C;G	222;222;221	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3998	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3002	166.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2110	2112	GCG	222;222;221	G;C;G	222;222;221	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3998	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3002	166.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2233	2235	GGC	206;206;207	G;G,C;C	206;205,1;207	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3998	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3002	166.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2242	2244	GGC	202;201;206	G;G;C	202;201;206	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3998	penA	1749	1749	100.0	penA.l15.c4.ctg.1	3002	166.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2260	2262	CCG	203;205;200	C,G,T;C,T;G,A	200,2,1;204,1;199,1	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5376	ponA	2397	2397	99.87	ponA.l15.c17.ctg.1	3497	191.7	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1682	1684	ACG	230;230;230	A,C;C,A;G	229,1;229,1;230	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5376	ponA	2397	2397	99.87	ponA.l15.c17.ctg.1	3497	191.7	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1820	1822	CTG	228;230;229	C;T;G	228;230;229	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2298	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2435	117.8	0	.	p	.	0	S22G	NONSYN	64	66	AGC	705	707	GGC	161;160;162	G;G;C	161;160;162	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2298	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2435	117.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	887	887	C	171	C	171	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	V258L	NONSYN	772	774	GTA	13	15	TTA	20;23;24	T;T;A	20;23;24	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	58	60	CAT	51;51;51	C;A;T	51;51;51	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	D274S	NONSYN	820	822	GAT	61	63	AGT	51;51;51	A;G;T	51;51;51	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	70	72	TAC	51;51;51	T;A;C	51;51;51	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	R307A	NONSYN	919	921	AGA	160	162	GCA	2;3;3	G;C;A	2;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	T311A	NONSYN	931	933	ACA	172	174	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	E312D	NONSYN	934	936	GAA	175	177	GAC	3;3;3	G;A;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	F314I	NONSYN	940	942	TTC	181	183	ATC	3;3;3	A;T;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	A316S	NONSYN	946	948	GCG	187	189	TCG	3;3;3	T;C;G	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	V318A	NONSYN	952	954	GTC	193	195	GCC	4;4;4	G;C;C	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	G319S	NONSYN	955	957	GGC	196	198	AGC	4;5;5	A;G;C	4;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	G320A	NONSYN	958	960	GGT	199	201	GCC	5;5;5	G;C;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	300	porB1a	984	222	90.54	porB1a.l15.c17.ctg.4	326	24.3	0	.	p	.	0	G322V	NONSYN	964	966	GGT	205	207	GTT	7;7;7	G;T;T	7;7;7	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2886	porB1b	1047	1047	98.85	porB1b.l15.c4.ctg.1	2026	176.8	0	.	p	.	0	T26A	NONSYN	76	78	ACC	689	691	GCC	250;250;246	G;C,T;C	250;249,1;246	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2886	porB1b	1047	1047	98.85	porB1b.l15.c4.ctg.1	2026	176.8	0	.	p	.	0	N38E	NONSYN	112	114	AAT	725	727	GAA	231;228;232	G;A,G;A	231;227,1;232	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2886	porB1b	1047	1047	98.85	porB1b.l15.c4.ctg.1	2026	176.8	0	.	p	.	0	K41D	NONSYN	121	123	AAA	734	736	GAC	237;237;238	G;A,C;C	237;236,1;238	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2886	porB1b	1047	1047	98.85	porB1b.l15.c4.ctg.1	2026	176.8	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1136	1138	TCA	236;236;237	T;C;A	236;236;237	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2886	porB1b	1047	1047	98.85	porB1b.l15.c4.ctg.1	2026	176.8	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1265	1267	GTC	242;241;242	G,T;T,A;C	241,1;240,1;242	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2886	porB1b	1047	1047	98.85	porB1b.l15.c4.ctg.1	2026	176.8	0	.	p	.	0	W257G	NONSYN	769	771	TGG	1382	1384	GGG	234;232;229	G;G;G,C	234;232;228,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2886	porB1b	1047	1047	98.85	porB1b.l15.c4.ctg.1	2026	176.8	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1595	1597	GCA	265;267;267	G;C;A,T	265;267;266,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2886	porB1b	1047	1047	98.85	porB1b.l15.c4.ctg.1	2026	176.8	1	SNP	p	G120K	1	.	.	358	360	AAG	971	973	AAG	208;208;208	A;A,T,C;G	208;206,1,1;208	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2886	porB1b	1047	1047	98.85	porB1b.l15.c4.ctg.1	2026	176.8	1	SNP	p	D121N	0	.	.	361	363	GAC	974	976	GAC	206;206;207	G;A;C	206;206;207	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2886	porB1b	1047	1047	98.85	porB1b.l15.c4.ctg.1	2026	176.8	1	SNP	p	A121D	1	.	.	361	363	GAC	974	976	GAC	206;206;207	G;A;C	206;206;207	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9594	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	5677	211.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2360	2362	AAT	267;261;261	A,C,T;A,T;T	264,2,1;260,1;261	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1488	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1564	118.2	1	SNP	p	V57M	1	.	.	169	171	ATG	845	847	ATG	265;266;267	A;T;G	265;266;267	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
